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Introduction
Oncocytomas are tumors composed of epithelial cells
with a large, granular and eosinophilic cytoplasm rich
in mitochondria. These tumors comprise less than 1% of
all salivary gland tumors.1 They occur most commonly
in patients between the ages of 55 and 70, without sex
predilection.2 Oncocytic carcinomas are even rarer and
estimated to represent 5%3 to 11%4 of all oncocytic
salivary gland neoplasms. Bauer and Bauer reported the
first case in 1953.5 The mean age at occurrence of these
malignancies is similar to that of benign oncocytomas,
with a male-to-female ratio of approximately 2:1.3,6
From a search of the available literature on MED-
LINE and PubMed, only 13 cases of oncocytic carcino-
mas arising from the nasal cavity have been reported
in the English, French and German literature.7–20 Most
of the cases were treated with surgery alone. In con-
trast, only 4 cases12,13,19,20 received radiotherapy as
adjuvant treatment following radical surgery or salvage
treatment for recurrence. Due to the rarity of this dis-
ease, what constitutes optimal treatment remains un-
clear. Whether or not surgery plus adjuvant radiotherapy
can procure durable local control is not known.
In this article, we report our experience of treating
a patient whose locally advanced primary tumor and
neck lymphadenopathies were controlled for nearly 2
years with combined surgery and intensity-modulated
radiotherapy (IMRT) of 66 Gy. To our knowledge, this
is the first report of oncocytic carcinoma that received
a high dose of radiation with the IMRT technique.
Case Report
An 80-year-old man, with a Karnofsky performance
status of 80, had no history of radiation exposure. He
had received surgical intervention twice at the otorhi-
nolaryngology department of Taipei Veterans General
Hospital for oncocytoma (Figure 1) of the right inferior
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A B
Figure 1. (A) Tubular structures and solid cell nests formed by columnar epithelial cells with eosinophilic granular cytoplasm (oncocytes);
neither cellular pleomorphism nor mitotic figures are seen (hematoxylin & eosin, 200×). (B) The eosinophilic granules in the cytoplasm
of the tumor cells are positive for phosphotungstic acid hematoxylin stain (400×).
turbinate in 1999 and 2004. Two years later, he pre-
sented with intermittent epistaxis. The sinus scope re-
vealed a soft tissue mass at the floor of the right nasal
cavity with easy contact bleeding. Mobile lymph nodes
were palpated at right levels II, IV and V, with the
largest measuring about 1.5 cm in size. The remainder
of the physical examination and laboratory data were
unremarkable. Computed tomography (CT) disclosed
a soft tissue mass in the right-side nasal chamber and
maxillary sinus, extending to the ethmoid sinus and 
orbit (Figure 2A), with enlarged lymphadenopathies 
in the right retropharyngeal, level II (Figure 2B), 
IV and V regions. The largest measured 1.5 cm in
diameter.
Skull base surgery via lateral rhinotomy was per-
formed. During operation, a bony tumor was found
obliterating the right maxillary sinus. The orbital floor,
nasolacrimal duct, lamina papyracea, ethmoid sinus,
right anterior skull base, frontal sinus, and sphenoid
sinus were invaded. Grossly, all visible tumors were
removed. Those specimens were labeled and sent for
pathologic examination. Because of the patient’s old
age and his family’s preference for conservative sur-
gery, neck dissection was not done.
Sections of the specimens showed respiratory
mucosal tissue and bone infiltrated by nests of large,
round-to-polyhedral epithelial cells with abundant fine,
granular and eosinophilic cytoplasm, and round vesic-
ular nuclei with mild nuclear atypia and rare mitosis
(Figure 3A). There were duct-like structures of vari-
able caliber in the tumor cell nests. The features of
tumor necrosis, perineural invasion, suspicious tumor
emboli in angiolymphatic spaces and bone destruction
(Figure 3B) were also identified. Fine purple-colored
granules in the cytoplasm of tumor cells were observed
on phosphotungstic acid hematoxylin (PTAH) stain.
The above findings were compatible with oncocytic
carcinoma. The status of the cut margins could not be
determined due to pieces of tumor tissue received in
this specimen.
Before adjuvant radiotherapy, whole-body positron
emission tomography (PET) scan with [F18]fluoro-
2-deoxy-D-glucose (FDG) was arranged to evaluate
the nature of the neck lymphadenopathies. It showed
several foci scattered along the right cervical chain from
levels II, IV and V with maximum standard uptake
values of 3.9, 3.7 and 2.9, respectively. Metastatic
lymphadenopathies were highly suspected (Figure 4A).
Increased uptakes were also noted in the right lobe of
the thyroid gland, mediastinum and right pulmonary
hilum. After comparing this PET image with neck CT
and consulting nuclear medicine physicians, we con-
sidered that the increased uptakes might represent
benign disease or nonspecific conditions in the above
areas.
Adjuvant radiotherapy was delivered utilizing 6-
and 10-MV photons via 7 intensity-modulated radia-
tion fields from a Varian 2100CD linear accelerator
(Varian, Palo Alto, CA, USA) and simultaneous in-
tegrated boost technique. The treatment planning
software we used was the Eclipse® system, version 6
(Varian). The prescribed radiation doses were 66 Gy
in 33 fractions to the right neck lymphadenopathies
[planning target volume-66 (PTV-66)], and 59.4 Gy
in 33 fractions to the whole neck plus the surgical bed
of the primary tumor, including the right nasal cavity,
maxillary sinus, ethmoid sinus, the floor and medial
wall of the orbit, the anterior wall of the sphenoid sinus,
and the lower portion of the right frontal sinus (PTV-
59.4; Figure 5). Of the PTV-66, 97.9% was covered
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by 66 Gy. Because of the proximity of the right orbital
fossa to the tumor bed, the mean and maximal doses
to the right optic nerve were 49.6 Gy and 61.7 Gy,
respectively. The mean and maximal doses to the right
eye were 27.2 Gy and 47.8 Gy, respectively. The doses
to the left optic nerve, eyeball, brain stem, spinal cord
and parotid gland were constrained within tolerance
limits. Acute toxicities including mucositis, dermatitis
and xerostomia were manageable at our outpatient
department. The patient completed the treatment with-
out interruption. Since he refused any feeding tube
during radiotherapy, a loss of 9% of his original body
weight was noted at the end of treatment despite sup-
portive care.
A
DC
B
Figure 2. (A, B) Computed tomography before surgery. Coronal view demonstrates tumor invasion of the nasal floor, right maxillary
sinus, ethmoid sinus and orbit. Axial view of the neck shows enlarged lymphadenopathy at right level II (arrow). (C, D) Computed tomog-
raphy 4 months after surgery and 1.5 months after radiotherapy. Coronal view shows postoperative features without recurrence. Axial
view of the neck reveals significant shrinkage of the lymph node (arrow).
A B
Figure 3. (A) Nuclear atypia and a mitotic figure (arrow; hematoxylin & eosin, 400×). (B) Bone destruction (hematoxylin & eosin, 200×).
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After adjuvant radiotherapy, the patient was re-
gularly followed-up at our otorhinolaryngology and
radiation oncology outpatient department, and sinus
scope showed no evidence of tumor recurrence, but
much crust over the right sinonasal cavity. The patient
had nasal and oral dryness, but there were no severe
late complications. Four months after surgery and 1.5
months after radiotherapy, follow-up CT revealed post-
operative features in the nasal cavity (Figure 2C) and
significant shrinkage of all right neck lymphadeno-
pathies. One of them is shown in Figure 2D. At 23
months after surgery, PET-CT did not show any
abnormalities in the neck (Figure 4B). Only 1 hyper-
metabolic spot remained in the right neck region,
compatible with thyroid lesion. The number of lesions
in the mediastinum and right hilum remained un-
changed. At the last ENT clinical visit, sinoscopy did
not show any sign of progression in the right nasal
A B
Figure 5. Dose distribution of the intensity-modulated radiotherapy plan. The spectrum from blue to red stands for doses from 60 Gy 
to 73.2 Gy, the maximal dose. Adequate coverage of target volume was achieved without exceeding the tolerance of critical structures.
(A) Coronal view of the face. (B) Axial view of the neck, showing level Ib and II lymphatic drainage.
A B
Figure 4. (A) Positron emission tomography before radiotherapy shows hypermetabolic lesions at right levels II, III and V, compatible
with lymphadenopathies; benign disease or nonspecific increased uptake were also noted in the right lobe of the thyroid (arrow) and
right pulmonary hilum. (B) Positron emission tomography 21 months after the completion of radiotherapy shows that the lesions with
high standard uptake value (> 2.5) in the right neck have disappeared, while others in the thyroid (arrow) and hilum remain unchanged.
The increased uptake of the right axillary lymph nodes, with maximal standard uptake value of 2.6, was judged to be a nonspecific find-
ing by the nuclear medicine physician.
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cavity and maxillary sinus. Magnetic resonance imag-
ing of the brain 1 month later and 2 years after surgery
also showed no sign of recurrence at the skull base and
paranasal sinuses.
Discussion
According to the World Health Organization classifi-
cation, oncocytic lesions are classified into 3 categories:
(1) oncocytosis or nodular oncocytic hyperplasia; (2)
oncocytoma; and (3) oncocytic carcinoma. Diagnosis
of malignancy in oncocytomas depends on the criteria
defined by Gray et al:21 destructive, infiltrating growth;
cellular pleomorphism with scattered mitoses; lympho-
vascular or perineural invasion; regional or distant
metastasis. Most of these carcinomas develop de novo,
although malignant transformations of preexisting on-
cocytomas after a long interval have been reported.3
Lymph node metastases occur in about 50–60% of
patients with oncocytic carcinoma of the head and
neck, but they may not play a critical role in overall
prognosis.3
Surgical excision is the widely accepted method of
treatment. Goode and Corio emphasized that aggres-
sive surgical intervention at initial presentation seems
to offer a more favorable prognosis.22 Due to the rar-
ity of oncocytic carcinomas, the role of radiotherapy
is controversial.6 Based on a case report of recurrence
after radiotherapy, Mahmoud suggested that these tu-
mors are radioresistant.12 In Mahmoud’s case, how-
ever, the radiotherapy was applied as salvage treatment
for the first recurrence, which developed 3 years after
the initial surgery. The radiation dose of 6,174 cGy 
is now considered inadequate, even for a malignant
tumor with “average” radiosensitivity; yet, the patient
remained free of disease until 10 years later. Goode
and Corio reported a case in which rapid and wide-
spread metastatic disease developed after conservative
surgery and radiotherapy, and suggested that radiation
does not appear to favorably alter the biologic behav-
ior of this tumor.22 In contrast, Chu and Strawitz rec-
ommended postoperative radiotherapy for oncocytic
carcinoma of the parotid gland.23 In an analysis of 36
cases with the same disease, Ardekian et al stated that
patients receiving combined surgery and radiation
therapy had less local recurrence than those who had
surgery only.6
In the 13 cases of oncocytic carcinomas arising from
the nasal cavity (Table 1), 4 received radiotherapy. In
the 2 cases who received radiotherapy for gross recur-
rent disease, 1 had a further 10-year disease-free period,
and another had complete response with no recurrence
after 1 year by clinical examination and biopsy. Radio-
therapy was prescribed in postoperative settings in the
other 2 cases. Although the number of cases is too small
to draw any conclusions, postoperative radiotherapy
seems to be a reasonable choice for gross or suspicious
microscopic residual disease. In addition, radiotherapy
may be an alternative treatment when surgery is not
feasible. IMRT can direct a high dose of radiation to
the tumor bed while sparing normal tissue. The tumor
control rate may be improved by using this technique.
Our case is the first of an oncocytic carcinoma patient
to receive a high dose of radiation (66 Gy) using the
IMRT technique. The acute toxicities were tolerable
in this old patient, and no severe late complications
were seen. Though the follow-up time is not long (he
is still alive at 25 months), we consider that surgery
plus aggressive radiotherapy might provide the best
chance of cure for locally advanced oncocytic carci-
noma of the nasal cavity.
PET is a useful tool for staging of head and neck
tumors and for detecting recurrence. Its role in the
evaluation of malignant salivary gland tumors, how-
ever, is more limited because of a relatively high false-
positive rate (approximately 30%). These PET-positive
benign tumors are most commonly Warthin’s tumors
or pleomorphic adenomas. It is worth mentioning that
Warthin’s tumors are composed of oncocytic cells, and
pleomorphic adenomas are frequently associated with
oncocytic change. In the literature, the experience of
FDG-PET in benign parotid oncocytoma is limited to
only 1 case, with a high standard uptake value.24 The
present case may be the first description of PET re-
sults in a patient with oncocytic carcinoma of the nasal
cavity with neck lymphadenopathies.
In conclusion, we have reported a case of locally
advanced oncocytic carcinoma of the nasal cavity with
clinically suspicious lymphadenopathies. After skull base
surgery combined with high-dose IMRT to the surgical
bed and neck, there was no local recurrence or distant
failure at 2 years. Radical surgery followed by adjuvant
radiotherapy might provide durable local control for
such disease.
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